Literature DB >> 20193040

Increased expression of cholesterol 24S-hydroxylase results in disruption of glial glutamate transporter EAAT2 association with lipid rafts: a potential role in Alzheimer's disease.

Guilian Tian1, Qiongman Kong, Liching Lai, Abhik Ray-Chaudhury, Chien-liang G Lin.   

Abstract

The glial glutamate transporter EAAT2 (excitatory amino acid transporter 2) is the major mediator of glutamate clearance that terminates glutamate-mediated neurotransmission. Loss of EAAT2 and associated glutamate uptake function has been reported in the brains of patients with Alzheimer's disease (AD). We previously reported that EAAT2 is associated with lipid raft microdomains of the plasma membrane. In the present study, we demonstrated that association of EAAT2 with lipid rafts is disrupted in AD brains. This abnormality is not a consequence of neuron degeneration, oxidative stress, or amyloid beta toxicity. In AD brains, cholesterol 24S-hydroxylase (CYP46), a key enzyme in maintenance of cholesterol homeostasis in the brain, is markedly increased in astrocytes but decreased in neurons. We demonstrated that increased expression of CYP46 in primary astrocytes results in a reduction of membrane cholesterol levels and leads to the dissociation of EAAT2 from lipid rafts and the loss of EAAT2 and associated glutamate uptake function. These results suggest that a disturbance of cholesterol metabolism may contribute to loss of EAAT2 in AD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20193040      PMCID: PMC3010752          DOI: 10.1111/j.1471-4159.2010.06661.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  42 in total

1.  Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients.

Authors:  D Lütjohann; A Papassotiropoulos; I Björkhem; S Locatelli; M Bagli; R D Oehring; U Schlegel; F Jessen; M L Rao; K von Bergmann; R Heun
Journal:  J Lipid Res       Date:  2000-02       Impact factor: 5.922

2.  On the turnover of brain cholesterol in patients with Alzheimer's disease. Abnormal induction of the cholesterol-catabolic enzyme CYP46 in glial cells.

Authors:  N Bogdanovic; L Bretillon; E G Lund; U Diczfalusy; L Lannfelt; B Winblad; D W Russell; I Björkhem
Journal:  Neurosci Lett       Date:  2001-11-13       Impact factor: 3.046

3.  Association of CYP46 intron 2 polymorphism in Finnish Alzheimer's disease samples and a global scale summary.

Authors:  S Helisalmi; S Vepsäläinen; A M Koivisto; A Mannermaa; S Iivonen; M Hiltunen; V Kiviniemi; H Soininen
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-03       Impact factor: 10.154

4.  24S-hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia.

Authors:  A Papassotiropoulos; D Lütjohann; M Bagli; S Locatelli; F Jessen; R Buschfort; U Ptok; I Björkhem; K von Bergmann; R Heun
Journal:  J Psychiatr Res       Date:  2002 Jan-Feb       Impact factor: 4.791

5.  Changes in the cellular distribution of glutamine synthetase in Alzheimer's disease.

Authors:  S R Robinson
Journal:  J Neurosci Res       Date:  2001-12-01       Impact factor: 4.164

6.  Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis.

Authors:  J D Rothstein; M Van Kammen; A I Levey; L J Martin; R W Kuncl
Journal:  Ann Neurol       Date:  1995-07       Impact factor: 10.422

7.  A novel action of alzheimer's amyloid beta-protein (Abeta): oligomeric Abeta promotes lipid release.

Authors:  M Michikawa; J S Gong; Q W Fan; N Sawamura; K Yanagisawa
Journal:  J Neurosci       Date:  2001-09-15       Impact factor: 6.167

8.  High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation.

Authors:  L Mucke; E Masliah; G Q Yu; M Mallory; E M Rockenstein; G Tatsuno; K Hu; D Kholodenko; K Johnson-Wood; L McConlogue
Journal:  J Neurosci       Date:  2000-06-01       Impact factor: 6.167

9.  Increased brain beta-amyloid load, phosphorylated tau, and risk of Alzheimer disease associated with an intronic CYP46 polymorphism.

Authors:  Andreas Papassotiropoulos; Johannes R Streffer; Magdalini Tsolaki; Simon Schmid; Dietmar Thal; Francesca Nicosia; Vassiliki Iakovidou; Alessia Maddalena; Dieter Lütjohann; Estifanos Ghebremedhin; Thomas Hegi; Thomas Pasch; Muriel Träxler; Annette Brühl; Luisa Benussi; Giuliano Binetti; Heiko Braak; Roger M Nitsch; Christoph Hock
Journal:  Arch Neurol       Date:  2003-01

10.  Human glioma cells and undifferentiated primary astrocytes that express aberrant EAAT2 mRNA inhibit normal EAAT2 protein expression and prevent cell death.

Authors:  Hong Guo; Liching Lai; Matthew E R Butchbach; Chien-liang Glenn Lin
Journal:  Mol Cell Neurosci       Date:  2002-12       Impact factor: 4.314

View more
  29 in total

Review 1.  Role of astrocytes in brain function and disease.

Authors:  Marta Sidoryk-Wegrzynowicz; Michal Wegrzynowicz; Eunsook Lee; Aaron B Bowman; Michael Aschner
Journal:  Toxicol Pathol       Date:  2010-11-12       Impact factor: 1.902

2.  Small-molecule activator of glutamate transporter EAAT2 translation provides neuroprotection.

Authors:  Qiongman Kong; Ling-Chu Chang; Kou Takahashi; Qibing Liu; Delanie A Schulte; Liching Lai; Brian Ibabao; Yuchen Lin; Nathan Stouffer; Chitra Das Mukhopadhyay; Xuechao Xing; Kathleen I Seyb; Gregory D Cuny; Marcie A Glicksman; Chien-Liang Glenn Lin
Journal:  J Clin Invest       Date:  2014-02-24       Impact factor: 14.808

Review 3.  Glutamate transporter EAAT2: regulation, function, and potential as a therapeutic target for neurological and psychiatric disease.

Authors:  Kou Takahashi; Joshua B Foster; Chien-Liang Glenn Lin
Journal:  Cell Mol Life Sci       Date:  2015-06-02       Impact factor: 9.261

Review 4.  Lipid rafts and neurodegeneration: structural and functional roles in physiologic aging and neurodegenerative diseases.

Authors:  Sara Grassi; Paola Giussani; Laura Mauri; Simona Prioni; Sandro Sonnino; Alessandro Prinetti
Journal:  J Lipid Res       Date:  2019-12-23       Impact factor: 5.922

5.  RETRACTED: Dysregulated glutamate and dopamine transporters in postmortem frontal cortex from bipolar and schizophrenic patients.

Authors:  Jagadeesh Sridhara Rao; Matthew Kellom; Edmund Arthur Reese; Stanley Isaac Rapoport; Hyung-Wook Kim
Journal:  J Affect Disord       Date:  2011-09-16       Impact factor: 4.839

6.  Esterification of 24S-OHC induces formation of atypical lipid droplet-like structures, leading to neuronal cell death.

Authors:  Wakako Takabe; Yasuomi Urano; Diep-Khanh Ho Vo; Kimiyuki Shibuya; Masaki Tanno; Hiroaki Kitagishi; Toyoshi Fujimoto; Noriko Noguchi
Journal:  J Lipid Res       Date:  2016-09-19       Impact factor: 5.922

7.  Structure-activity relationship study of pyridazine derivatives as glutamate transporter EAAT2 activators.

Authors:  Xuechao Xing; Ling-Chu Chang; Qiongman Kong; Craig K Colton; Liching Lai; Marcie A Glicksman; Chien-Liang Glenn Lin; Gregory D Cuny
Journal:  Bioorg Med Chem Lett       Date:  2011-08-08       Impact factor: 2.823

Review 8.  Battling Alzheimer's Disease: Targeting SUMOylation-Mediated Pathways.

Authors:  Wagner Carbolin Martins; Carla Inês Tasca; Helena Cimarosti
Journal:  Neurochem Res       Date:  2015-07-31       Impact factor: 3.996

9.  Glutamate transporter EAAT2: a new target for the treatment of neurodegenerative diseases.

Authors:  Chien-Liang Glenn Lin; Qiongman Kong; Gregory D Cuny; Marcie A Glicksman
Journal:  Future Med Chem       Date:  2012-09       Impact factor: 3.808

Review 10.  Interaction of membrane/lipid rafts with the cytoskeleton: impact on signaling and function: membrane/lipid rafts, mediators of cytoskeletal arrangement and cell signaling.

Authors:  Brian P Head; Hemal H Patel; Paul A Insel
Journal:  Biochim Biophys Acta       Date:  2013-07-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.